ImmTACs: Novel bi-specific agents for targeted cancer therapy

Our expanding knowledge of the immune system is guiding a new era of targeted anticancer therapies. Here, we describe our recent work on a novel class of anticancer agents termed ImmTACs. These molecules combine the power of picomolar-affinity TCR-based antigen recognition with the immune-activating...

Descripción completa

Detalles Bibliográficos
Autores principales: Oates, Joanne, Jakobsen, Bent K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601161/
https://www.ncbi.nlm.nih.gov/pubmed/23525668
http://dx.doi.org/10.4161/onci.22891
_version_ 1782475727392735232
author Oates, Joanne
Jakobsen, Bent K.
author_facet Oates, Joanne
Jakobsen, Bent K.
author_sort Oates, Joanne
collection PubMed
description Our expanding knowledge of the immune system is guiding a new era of targeted anticancer therapies. Here, we describe our recent work on a novel class of anticancer agents termed ImmTACs. These molecules combine the power of picomolar-affinity TCR-based antigen recognition with the immune-activating potential of an anti-CD3 antibody fragment, to potently redirect T-cell killing to tumor cells.
format Online
Article
Text
id pubmed-3601161
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36011612013-03-22 ImmTACs: Novel bi-specific agents for targeted cancer therapy Oates, Joanne Jakobsen, Bent K. Oncoimmunology Author's View Our expanding knowledge of the immune system is guiding a new era of targeted anticancer therapies. Here, we describe our recent work on a novel class of anticancer agents termed ImmTACs. These molecules combine the power of picomolar-affinity TCR-based antigen recognition with the immune-activating potential of an anti-CD3 antibody fragment, to potently redirect T-cell killing to tumor cells. Landes Bioscience 2013-02-01 /pmc/articles/PMC3601161/ /pubmed/23525668 http://dx.doi.org/10.4161/onci.22891 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Oates, Joanne
Jakobsen, Bent K.
ImmTACs: Novel bi-specific agents for targeted cancer therapy
title ImmTACs: Novel bi-specific agents for targeted cancer therapy
title_full ImmTACs: Novel bi-specific agents for targeted cancer therapy
title_fullStr ImmTACs: Novel bi-specific agents for targeted cancer therapy
title_full_unstemmed ImmTACs: Novel bi-specific agents for targeted cancer therapy
title_short ImmTACs: Novel bi-specific agents for targeted cancer therapy
title_sort immtacs: novel bi-specific agents for targeted cancer therapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601161/
https://www.ncbi.nlm.nih.gov/pubmed/23525668
http://dx.doi.org/10.4161/onci.22891
work_keys_str_mv AT oatesjoanne immtacsnovelbispecificagentsfortargetedcancertherapy
AT jakobsenbentk immtacsnovelbispecificagentsfortargetedcancertherapy

Ejemplares similares